Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On May 25, 2021, Adamis Pharmaceuticals Corporation (the "Company") received a
notification letter (the "Notice") from the Listing Qualifications Department of
The Nasdaq Stock Market LLC ("NASDAQ") notifying the Company that, because the
Company has not yet filed its Quarterly Report on Form 10-Q for the period ended
March 31, 2021 (the "Filing" or the "Form 10-Q"), the Company is no longer in
compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing
of periodic reports with the Securities and Exchange Commission (the "SEC").
The Notice also indicated that the Company has 60 calendar days to submit a plan
to regain compliance and, if NASDAQ accepts the plan, NASDAQ can grant an
exception of up to 180 calendar days from the Filing's due date to regain
compliance. The Company may regain compliance at any time during this 180-day
period upon filing with the SEC its Form 10-Q, as well as all subsequent
required periodic financial reports that are due within that period. If NASDAQ
does not accept the Company's plan, the Company will have the opportunity to
appeal that decision to a NASDAQ Hearings Panel. The Notice was issued in
accordance with standard NASDAQ procedures and has no immediate effect on the
listing of the Company's common stock on the NASDAQ Capital Market.
Item 7.01 Regulation FD Disclosure.
On May 28, 2021, the Company issued a press release disclosing the Company's
receipt of the Notice. A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
The information contained in this Item 7.01, including Exhibit 99.1 hereto, is
being furnished and shall not be deemed "filed" for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any registration statement or other filing under
the Securities Act of 1933, as amended or the Exchange Act, except as shall be
expressly set forth by specific reference to such filing.
Cautionary Note Regarding Forward-Looking Statements. This Current Report on
Form 8-K and the press release furnished as Exhibit 99.1 hereto may contain
forward-looking statements which involve certain risks and uncertainties that
could cause actual results to differ materially from those expressed or implied
by these statements. Please refer to the note in the press release under the
heading "Adamis Forward-Looking Statements."
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
99.1 Press Release, dated May 28, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
© Edgar Online, source Glimpses